StockNews.AI
VIR
StockNews.AI
91 days

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

1. VIR executives will speak at the TD Cowen Oncology Summit on May 27. 2. The discussion will focus on cancer and infectious disease treatments. 3. A webcast will be available for investors post-event. 4. VIR's portfolio includes treatments for cancer and chronic hepatitis delta.

3m saved
Insight
Article

FAQ

Why Bullish?

Executives speaking shows confidence and engagement that can attract investor interest. Historical examples show similar events tend to positively influence biotech stocks.

How important is it?

The event highlights innovative research efforts and investor engagement from VIR, crucial for price impact.

Why Short Term?

Immediate interest and potential stock movement may occur from the event’s exposure. Previous summit discussions have caused short-term price fluctuations.

Related Companies

BMYMRNANVAX
- SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. More News From Vir Biotechnology, Inc.

Related News